机制是否重要:穿透性与钝性肝创伤肝动脉栓塞疗效比较的系统综述(已撤稿)
该系统综述按PRISMA指南检索2014至2024年文献,纳入8项研究共7397例肝创伤患者(钝性3980例占53.8%,穿透性3417例占46.2%),比较肝动脉栓塞在两种致伤机制下的结局。结果显示钝性伤临床成功率94.1%(95%CI 92.8-95.4%)高于穿透伤85.4%(95%CI 83.7-87.1%),再出血钝性伤7.8%(95%CI 6.7-8.9%)低于穿透伤14.1%(95%CI 12.7-15.5%),穿透伤总体死亡率14.9%对5.7%、肝相关死亡7.2%对1.9%,肝坏死、脓肿、胆漏等并发症及住院和ICU时间均以穿透伤更高更长(均P<0.05)。作者据此建议按机制制定栓塞方案并对穿透伤加强监测。该文已撤稿。
要点
- 钝性肝创伤肝动脉栓塞临床成功率94.1%(95%CI 92.8-95.4%),高于穿透伤的85.4%(95%CI 83.7-87.1%),P<0.05。
- 穿透性肝创伤栓塞后再出血14.1%(95%CI 12.7-15.5%),高于钝性伤的7.8%(95%CI 6.7-8.9%),P<0.05。
- 穿透伤总体死亡率14.9%、肝相关死亡7.2%,分别高于钝性伤的5.7%和1.9%(均P<0.05)。
- 肝坏死、脓肿、胆漏等并发症在穿透伤更常见(P<0.05),住院9.0天对6.7天、ICU 5.3天对3.8天均更长(P<0.05)。
- 作者建议采用按致伤机制区分的方案、对穿透伤加强监测,并考虑对高级别穿透伤加用外科辅助手段。
适用人群与场景
- 纳入报告肝创伤肝动脉栓塞结局、且含钝性与穿透性损伤比较数据的研究人群,共7397例,其中钝性3980例(53.8%)、穿透性3417例(46.2%)。
处置流程与药物剂量
- 作者推荐采用按致伤机制区分的方案,并对穿透性肝损伤加强监测。
- 作者建议对高级别穿透性肝创伤考虑加用外科辅助手段。
- 作者建议按损伤类型标准化肝动脉栓塞方案以改善结局。
研究设计与关键结果
- 系统综述纳入8项研究共7397例肝创伤患者,钝性3980例(53.8%)、穿透性3417例(46.2%),检索2014至2024年文献。
- 主要结局:钝性伤栓塞临床成功率94.1%(95%CI 92.8-95.4%)高于穿透伤85.4%(95%CI 83.7-87.1%),P<0.05。
- 再出血:钝性伤7.8%(95%CI 6.7-8.9%)低于穿透伤14.1%(95%CI 12.7-15.5%),P<0.05。
- 死亡率:穿透伤总体死亡14.9%、肝相关死亡7.2%,钝性伤分别为5.7%和1.9%(均P<0.05)。
- 并发症:肝坏死、脓肿、胆漏在穿透伤更常见(P<0.05)。
- 住院时间穿透伤9.0天对钝性伤6.7天,ICU停留5.3天对3.8天,均以穿透伤更长(P<0.05)。
证据类型、等级与局限
- 证据类型:系统综述/Meta分析,证据等级Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对穿透性肝创伤行肝动脉栓塞者,再出血(14.1%对7.8%)、死亡(总体14.9%对5.7%)及并发症均高于钝性伤,作者据此建议对此类患者加强监测。
- 作者建议按致伤机制标准化栓塞方案,并对高级别穿透性肝创伤考虑外科辅助手段。
- 本文已撤稿,临床决策时需注意该文献状态。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Angioembolization (AE) has emerged as a key adjunct in the nonoperative management of hepatic trauma; however, its effectiveness and complication rates may differ based on the mechanism of injury. While AE is widely used for both blunt and penetrating hepatic trauma, limited research has directly compared outcomes between these trauma mechanisms. This systematic review addresses this gap by analyzing AE success rates, complications, and patient outcomes based on the mechanism of hepatic trauma.
METHODS: A systematic review was conducted per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, identifying studies published between 2014 and 2024 through comprehensive database searches. Eligible studies reported AE outcomes in hepatic trauma with comparative data for blunt and penetrating injuries. Primary outcomes included clinical success, rebleeding, mortality, and hepatic-related deaths. Secondary outcomes included complications and length of stay. Weighted means with 95% confidence intervals (CIs) were calculated.
RESULTS: Eight studies encompassing 7,397 patients met the inclusion criteria (3,980 blunt [53.8%], 3,417 penetrating [46.2%]). Angioembolization showed higher clinical success in blunt trauma (94.1%; 95% CI, 92.8-95.4%) versus penetrating trauma (85.4%; 95% CI, 83.7-87.1%; p < 0.05). Rebleeding was lower in blunt trauma (7.8%; 95% CI, 6.7-8.9%) than penetrating trauma (14.1%; 95% CI, 12.7-15.5%; p < 0.05). Penetrating trauma had higher overall mortality (14.9% vs. 5.7%) and hepatic-related deaths (7.2% vs. 1.9%; p < 0.05 for both). Complications such as hepatic necrosis, abscesses, and bile leaks were more frequent in penetrating injuries ( p < 0.05). Hospital (9.0 vs. 6.7 days) and intensive care unit stays (5.3 vs. 3.8 days) were also significantly longer ( p < 0.05).
CONCLUSION: Angioembolization is more effective in blunt hepatic trauma, with higher success rates, fewer complications, and improved survival. We recommend (1) mechanism-specific protocols with enhanced monitoring for penetrating injuries, (2) consideration of surgical adjuncts for high-grade penetrating trauma, and (3) standardizing AE protocols by injury type to improve outcomes.
LEVEL OF EVIDENCE: Systematic Review/Meta analysis; Level III.
参考来源
- Monge KM, Aragón Conrado LE, Fulginiti D, et al. Does mechanism matter: A comparative systematic review of liver embolization in penetrating versus blunt trauma [RETRACTED]. J Trauma Acute Care Surg. 2025. PMID: 40828388. doi:10.1097/TA.0000000000004762
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。